Prior authorization is a benefit gate, not a prescribing gate. A benefit manager’s clinical unit drafts a written rule set, the plan sponsor decides whether to adopt that standard version or a customized one, and a reviewer then checks a submitted request against whichever document applies. The prescription remains valid regardless of the answer.
Dr. Kent Holtorf, MD
Three parties, three different jobs
The confusion in this process comes from treating the benefit manager as a single actor. It is not. OptumRx builds drug lists and utilization rules and sells them as products to plan sponsors. The sponsor buys a package. A reviewer then applies the purchased rules to individual cases. Those are three separate functions, and only the first two decide anything about policy.
This is why arguing clinical merit to a reviewer rarely helps. The reviewer is checking a submission against a document written elsewhere and bought by someone else. A request either contains what the document asks for or it does not.
Who controls what
| Party | Controls | Does not control |
|---|---|---|
| Plan sponsor | Whether the category is covered and which rule set applies | How an individual case is scored |
| Benefit manager clinical committee | The standard drug list and standard criteria documents | Whether a sponsor adopts them |
| Reviewer handling the request | Whether the submission meets the written criteria | The criteria themselves |
| Prescribing office | What clinical evidence gets submitted | The standard applied to it |
| Dispensing pharmacy | Transmitting the claim correctly | Any part of the review |
Template versus custom rule sets
Benefit managers publish a standard drug list that most clients adopt as delivered. Larger sponsors, particularly self-funded employers with the scale to negotiate, commission a customized version instead. The customized version can add categories, remove them, tighten conditions, or loosen them.
Both members are administered by the same company. Neither is being treated inconsistently. They simply bought different products. Any general statement about how a benefit manager handles weight-management medication collapses on contact with this fact, which is why the plan’s own posted criteria document is the only reliable source for a given member.
Exclusion lists sit above the criteria entirely
Separate from the drug list, benefit managers maintain exclusion lists naming products that will not be paid for under plans adopting that list, typically because a clinically similar alternative is preferred. A drug on an exclusion list never reaches the authorization stage. The claim fails earlier, on coverage rather than on criteria, and submitting a beautifully documented request against an excluded product produces a refusal that no amount of evidence changes.
Checking whether a product is excluded before assembling a request saves weeks. The distinction between “excluded” and “requires review” is the single most useful thing to establish at the outset.
When a product turns out to be excluded rather than merely gated, the practical next move is pricing it outside the plan, and direct sellers make that easy to begin. HealthRX posts an open Zepbound page laying out how it prescribes and charges for the drug, while Henry Meds, LillyDirect, and NovoCare each list separate terms. Comparing a handful of them turns a hard exclusion into a straightforward cost question rather than a wall.
Why preferred products move
Placement on a drug list reflects two inputs: a clinical committee’s read of the evidence, and net cost after manufacturer rebates negotiated by the benefit manager. Both are ordinary features of the market and both are disclosed in general terms in benefit contracts. When two products in a class are judged clinically comparable, net cost decides which one sits in the preferred position, and that position can change when contracts renew.
Head-to-head evidence does exist in this class. A randomized comparison of semaglutide and tirzepatide has been published, as have separate trials of each agent against placebo. Committees weigh that literature, but they weigh it alongside price, and a product losing preferred placement has not necessarily lost a clinical argument.
Two indications, two different requests
Zepbound’s label covers long-term weight reduction and maintenance, and separately, moderate to severe obstructive sleep apnea in adults with obesity. Those are distinct approved uses supported by distinct trial programs, and a plan may treat them as distinct benefit questions. A request that does not state which indication is being sought invites a review against the wrong document. Naming it explicitly, with the supporting diagnosis, is the cheapest improvement available to any submission.
What to do while a decision is outstanding
Reviews take time, and treatment plans do not pause politely. Pricing the alternatives during that window turns a later refusal into an inconvenience rather than an interruption. Manufacturer self-pay pharmacies list their figures publicly, and clinician-supervised cash services publish flat monthly rates for compounded preparations, which are made by compounding pharmacies and are not FDA-approved products. A published monthly price is only interpretable alongside the provider behind it, since services differ on what the fee includes, whether a clinician is genuinely involved, and which pharmacy dispenses. Comparing several, including established names such as Ro and Hims and Hers, gives the number context.
Frequently asked questions
Can a prescriber overrule a refused authorization?
No. A prescriber controls the prescription, not the benefit. A refusal means the plan will not pay under the terms the sponsor bought. The prescription stays valid and can be filled by any route the patient is willing to fund, including full cash payment at a pharmacy.
Why do two people on the same insurer get different answers?
Because the rule set is bought per plan. One employer may adopt a standard drug list unchanged while another commissions a customized version with different categories and conditions. The administrator is identical, the purchased product is not, and outcomes follow the purchase.
Is an approval permanent once granted?
No. Authorizations carry an end date and typically require renewal with updated clinical information. They can also lapse when the plan year turns over or when the sponsor changes benefit administrators, because the new record contains no history of the earlier decision.
Does an authorization guarantee the pharmacy claim will pay?
Not by itself. An approved review clears the clinical gate, but the claim must still satisfy quantity rules, refill timing, and any channel restriction directing the fill to a specialty or mail pharmacy. Those checks run separately at the counter.
Should the request quote clinical guidelines?
It can help as context, but the criteria document controls the outcome. Published obesity pharmacotherapy guidance describes good practice; the reviewer is checking a purchased rule set. Meeting the document beats arguing the literature, and the two are not always aligned.
